The CGM maker raised its full-year revenue outlook to $5.18bn-$5.25bn after reporting $1.3bn in Q2 sales.
Dexcom reported Q2 revenue of $1.3bn, a 13% year-over-year increase, prompting a slight upward revision to its 2026 revenue forecast. The company now expects revenue between $5.18bn and $5.25bn, up from a prior range of $5.16bn to $5.25bn.
The revised outlook reflects growth of 11%-13% for the year. Dexcom’s shares rose over 8% to $81.04 in early trading on 31 July, following the release of results after market close on 30 July. The company’s market capitalization stands at approximately $29bn.
Recent milestones include FDA clearance for its Stelo glucose biosensor system for children and positive trial data for its G7 CGM in type 2 diabetes patients not using insulin.